BGB-11417-303
Not yet recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Study Overview
Sex:
All 
Age: 18 Years / N/A
No Study Documents
Locations
Study Overview
Sex:
All
Age: 18 Years / N/A
No Study Documents